Cross-presentation of tumour antigen is essential for priming tumour-reactive CD8*T cells. However. the effect of tumour antigen characteristics on cross-present at ion efficiency is poorly understood. Such knowledge could facilitate the rational selection of tumour antigens for cancer immunotherapy. This thesis investigated the relationship between the level of tumour antigen in different cellular compartments and cross-presentation efficiency, demonstrating that nuclear antigen is not cross presented as efficiently as secreted and cytoplasmic antigens at low concentrations. However, chemotherapy-induced tumour cell death reversed this inefficiency. These findings may have important implications for the design of therapeutic strategies that target nuclear antigens.
|Qualification||Doctor of Philosophy|
|Award date||3 Nov 2016|
|Publication status||Unpublished - 2016|